References
- FoulksGNJesterJVMurubeJ2007 Report of the international dry eye workshop (DEWS)Ocul Surf20075265204
- LiDQChenZSongXJLuoLPflugfelderSCStimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cellsInvest Ophthalmol Vis Sci2004454302431115557436
- YehSSongXJFarleyWLiDQSternMEPflugfelderSCApoptosis of ocular surface cells in experimentally induced dry eyeInvest Ophthalmol Vis Sci20034412412912506064
- PerezVLPflugfelderSCZhangSShojaeiAHaqueRLifitegrast, a novel integrin antagonist for treatment of dry eye diseaseOcul Surf201614220721526807723
- GaoJMorganGTieuDICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patient and Sjögrens syndrome-like MRL/lpr miceExp Eye Res200478482383515037117
- SembaCPGadekTRDevelopment of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye diseaseClin Ophthalmol2016101083109427354762
- ZhongMGadekTRBuiMDiscovery and development of potent LFA-1/ICAM-1 antagonist SAR 1118 as ophthalmic solution for treating dry eyeACS Med Chem Lett20123320320624900456
- LamHBleidenLde PaivaCSFarleyWSternMEPflugfelderSCTear cytokine profiles in dysfunctional tear syndromeAm J Ophthalmol200914719820518992869
- GadekTRBurdickDJMcDowellRSGeneration of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small moleculeScience20022951086109011834839
- RaoVRPrescottEShelkeNBDelivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathyInvest Ophthalmol Vis Sci2010515198520420445119
- SembaCPTorkildsenGLLonsdaleJDA phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eyeAm J Ophthalmol201215361050106022330307
- SheppardJDTorkildsenGLLonsdaleJDLifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 studyOphthalmology2014121247548324289915
- TauberJKarpeckiPLatkanyRLifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 studyOphthalmology2015122122423243126365210
- HollandEJLuchsJKarpeckiPMLifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3)Ophthalmology20171241535928079022
- DonnenfeldEDKarpeckiPMMajmudarPASafety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-year, multicenter, randomized, placebo-controlled studyCornea201635674174827055211